Key facts
- This page summarizes James Timothy Patrick Ryan's Form 3 filing for BioNTech SE (BNTX).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 25 Mar 2026, 17:57.
James Timothy Patrick Ryan - 18 Mar 2026 Form 3 Insider Report for BioNTech SE (BNTX)
- Reporting relationship
- Chief Legal Officer and Chief Business Officer; Exhibit List - Exhibit 24 - Power of Attorney
- Issuer ticker
- BNTX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 25 Mar 2026, 17:57:30 UTC
- Next SEC filing
- 13 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Humza Bokhari, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
James Timothy Patrick Ryan filed Form 3 for BioNTech SE (BNTX) on 25 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002123964
Primary reporting owner
Ryan James Timothy Patrick
- Relationship
- Chief Legal Officer and Chief Business Officer; Exhibit List - Exhibit 24 - Power of Attorney
- Address
- C/O BIONTECH SE, AN DER GOLDGRUBE 12, MAINZ, GERMANY
- Signature
- /s/ Humza Bokhari, Attorney-in-Fact
- Signature date
- 25 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BNTX
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,795
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNTX
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 25,459
- Exercise price
- Footnotes
- F2, F3, F4, F5
BNTX
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 8,838
- Exercise price
- Footnotes
- F2, F3, F5, F6
BNTX
holding
Derivative
Performance Share Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 11,047
- Exercise price
- $0.000000
- Footnotes
- F7
BNTX
holding
Derivative
Restricted Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 740
- Exercise price
- Footnotes
- F8, F9, F10
BNTX
holding
Derivative
Restricted Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 750
- Exercise price
- Footnotes
- F8, F9, F10
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
Includes 3,990 shares held jointly with the Reporting Person's spouse.
Footnote F2
The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
Footnote F3
The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.
Footnote F4
The exercise price of this option is EUR 75.91.
Footnote F5
Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.
Footnote F6
The exercise price of this option is EUR 93.35.
Footnote F7
Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
Footnote F8
The restricted stock units ("RSUs") vest in equal annual installments over four years commencing on the grant date and are subject to a four-year waiting period.
Footnote F9
The RSUs may be settled in ordinary shares, ADSs, and/or cash at the election of the plan administrator.
Footnote F10
Each RSU represents a contingent right to receive one ordinary share, one ADS, and/or the cash equivalent thereof at the election of the plan administrator.
SEC remarks
Chief Legal Officer and Chief Business Officer; Exhibit List - Exhibit 24 - Power of Attorney